home / stock / halo / halo quote
Last: | $52.01 |
---|---|
Change Percent: | -0.31% |
Open: | $51.46 |
Close: | $52.01 |
High: | $52.415 |
Low: | $50.93 |
Volume: | 839,303 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$52.01 | $51.46 | $52.01 | $52.415 | $50.93 | 839,303 | 07-03-2024 |
$51.3 | $51.95 | $51.3 | $52.11 | $50.68 | 1,039,654 | 07-02-2024 |
$52.02 | $52.23 | $52.02 | $53.22 | $51.53 | 1,364,220 | 07-01-2024 |
$52.36 | $51.84 | $52.36 | $52.59 | $51.24 | 2,334,652 | 06-28-2024 |
$51.63 | $52.25 | $51.63 | $52.35 | $51.53 | 874,950 | 06-27-2024 |
$52 | $52.06 | $52 | $52.13 | $51.326 | 1,171,716 | 06-26-2024 |
$52.4 | $52.49 | $52.4 | $52.68 | $51.81 | 1,124,184 | 06-25-2024 |
$52.06 | $52.4 | $52.06 | $52.92 | $51.72 | 1,278,818 | 06-24-2024 |
$51.55 | $51.12 | $51.55 | $52.21 | $50.82 | 3,554,275 | 06-21-2024 |
$50.86 | $50.11 | $50.86 | $51.19 | $49.45 | 1,154,736 | 06-20-2024 |
$50.27 | $49.74 | $50.27 | $50.838 | $48.995 | 1,035,344 | 06-19-2024 |
$50.27 | $49.74 | $50.27 | $50.838 | $48.995 | 1,035,344 | 06-18-2024 |
$49.66 | $49.48 | $49.66 | $49.7 | $48.25 | 1,007,258 | 06-17-2024 |
$49.5 | $49.095 | $49.5 | $49.77 | $48.495 | 1,418,017 | 06-14-2024 |
$49.62 | $49.32 | $49.62 | $49.9125 | $48.86 | 1,363,862 | 06-13-2024 |
$49.66 | $51 | $49.66 | $51.03 | $49.46 | 1,674,528 | 06-12-2024 |
$49.92 | $50.84 | $49.92 | $51.22 | $49.53 | 1,286,775 | 06-11-2024 |
$51.16 | $49.27 | $51.16 | $51.66 | $49.1719 | 2,183,853 | 06-10-2024 |
$50.85 | $51.08 | $50.85 | $51.98 | $50.3901 | 1,849,643 | 06-07-2024 |
$51.44 | $48 | $51.44 | $53 | $47.33 | 4,604,433 | 06-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire OCREVUS ® subcutaneous (SC) injection offers a new 10-minute administration with comparable effica...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...